Sign In
Buy RVMD
$155.99
+4.68 (+3.09%)
At Close: Jun 03, 2026
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
01:52am, Friday, 09'th Jan 2026
Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32
Merck in talks to buy biotech Revolution Medicines, FT reports
03:56pm, Thursday, 08'th Jan 2026
Merck is in talks to buy cancer drug developer Revolution Medicines , the Financial Times reported on Thursday, citing people familiar with the matter.
RVMD Stock Hits a Record High on Rumored Takeover Interest
10:16am, Thursday, 08'th Jan 2026
Revolution Medicines shares jump nearly 29% to a record high after a WSJ report said AbbVie showed takeover interest, a claim the pharma giant later denied.
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
08:00am, Thursday, 08'th Jan 2026
Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previ
AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.
07:38am, Thursday, 08'th Jan 2026
Shareholders in both drugmakers appear disappointed that a deal may not happen.
Breakfast News: Defense Stocks Whipsaw
07:30am, Thursday, 08'th Jan 2026
Trump puts pressure on defense contractors, Globus Medical soars on preliminary results, and more
Why Revolution Medicines Shares Are Sliding After Hours On Wednesday
03:13am, Thursday, 08'th Jan 2026
Shares of Revolution Medicines tumbled in after-hours trading on Wednesday after AbbVie denied reports that it was in talks to acquire the cancer-drug developer.
AbbVie in talks to buy biotech Revolution Medicines, WSJ reports
02:58pm, Wednesday, 07'th Jan 2026
AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
AbbVie Near Deal for Revolution Medicines
02:48pm, Wednesday, 07'th Jan 2026
The cancer-drug biotech firm has a market value around $16 billion.
Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Monday, 05'th Jan 2026
REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
Mark Goldsmith Sells 15,394 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
04:30am, Saturday, 20'th Dec 2025
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) insider Mark Goldsmith sold 15,394 shares of Revolution Medicines stock in a transaction dated Tuesday, December 16th. The shares were sold
Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 05'th Dec 2025
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
American Century Companies Inc. Has $16.72 Million Stock Holdings in Revolution Medicines, Inc. $RVMD
03:18am, Wednesday, 03'rd Dec 2025
American Century Companies Inc. reduced its holdings in Revolution Medicines, Inc. (NASDAQ: RVMD) by 38.7% in the undefined quarter, according to the company in its most recent filing with the SEC. Th
AXQ Capital LP Takes $282,000 Position in Revolution Medicines, Inc. $RVMD
03:34am, Tuesday, 25'th Nov 2025
AXQ Capital LP bought a new position in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and E
Revolution Medicines, Inc. (RVMD) Presents at Jefferies London Healthcare Conference 2025 Transcript
11:48am, Tuesday, 18'th Nov 2025
Revolution Medicines, Inc. ( RVMD ) Jefferies London Healthcare Conference 2025 November 18, 2025 4:30 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Conference Call Participan
